HPV Associated Disorders Treatment Market Analysis

 Treatment Type (Medication, Surgery)

Medication is projected to dominate the treatment type segment during the forecast period. Primary drivers for the segment’s growth include the increased availability of antiviral and immunomodulatory drugs. These drugs target HPV-related infections and complications including genital warts and cervical dysplasia. The rising incidence of HPV-associated cancers such as cervical, anal, and oropharyngeal cancers, has also boosted the demand for therapeutic medicines. Moreover, drug formulation advances, including topical creams, oral medications, and injectables, have made treatments more effective and accessible to patients.

The shift towards non-invasive options, compared to more aggressive treatments such as surgery, has further enhanced the adoption of medication as the preferred treatment method. Ongoing research and clinical trials in HPV vaccines and therapeutic drugs are expected to boost the segment’s growth. For instance, in March 2024, Bayer AG and Thermo Fisher Scientific Inc. announced a collaboration to develop NGS-based CDx, for cancer medicines. The collaboration focuses on creating advanced diagnostics that enable more precise and personalized medicinal treatments for patients with HPV-related cancers.  As newer medications enter the market, the segment’s growth is anticipated to reach greater heights.

End use (Hospitals, Ambulatory Surgical Centers)

Hospitals segment is set to account for around 45.1% HPV associated disorders treatment market share by 2037. The availability of advanced medical infrastructure in hospitals allows complex treatment administration such as surgical procedures, radiation therapy, and advanced medications for HPV-related conditions. Furthermore, hospitals are also equipped with multidisciplinary teams of specialists, providing comprehensive care for HPV- associated disorders. Hospitals also have access to the latest diagnostic tools, including next-generation sequencing, and molecular diagnostics, which are crucial for early detection of diseases.

Government support and insurance coverage for hospital-based treatments also play a key role in strengthening their position in the HPV treatment landscape. For instance, as stated in a report by the American Hospital Association, approximately 90 percent of U.S. residents have health insurance with significant gains in health coverage occurring over the past five years. The Pradhan Mantri Jan Arogya Yojana (PM-JAY) is a flagship scheme of the Government of India. The health assurance scheme aims at providing a health cover of Rs. 5 lakhs per family per year for secondary and tertiary care hospitalization to over 12 crores of poor and vulnerable families that form the bottom 40% of the Indian population. Such factors are projected to further boost the segment’s growth in the forthcoming years.

Our in-depth analysis of the HPV associated disorders treatment market includes the following segments